Recently, increasing adiponectin levels have been associated with a lower risk of developing diabetes across populations in a dose–response relationship; however, dysregulation of adiponectin has been implicated in obesity, metabolic syndrome, type 2 diabetes, hypertension, and cardiovascular disease [163]. This evidence concerns the gene ADIPOQ and metabolic syndrome.